Together with our network of international partners, we consider it essential to fully investigate cannabis-based medicine in order to understand their mode of action. Based on this research, we are constantly improving our product-portfolio and developing new preparations made from the cannabis plant. We have the ambition to provide patients, with the best possible cannabinoid-treatment and provide physicians and pharmacists with education about the cannabis-plant.
Connect 4 is founding partner of CanPharma and is extending our expertise, when it comes to questions regarding market access for pharmaceuticals and medical devices. Among others Connect 4 has years of experiences in the fields of regulatory affairs, market intelligence, market entry and market penetration. Together with the Connect 4 team, we are expanding the variety of products on the market with new, great cannabis-based pharmaceuticals.
Together with CBM Labs, we are focusing on the bio-synthetic production of cannabinoids. CBM Labs is based in the Netherlands and already filed in several patents in order to develop formulations based on cannabinoids. Furthermore, CanPharma will provide CBM Labs with cannabis-based pharmaceuticals for research purposes and CBM Labs will support CanPharma to improve the quality of its product varieties to ensure patient-oriented medicine.